This episode unpacks Gossamer Bio $GOSS and a biotech breakdown where trial design risks collided with investor expectations. Built for biotech investors, traders, and market watchers, we explore Phase three trials, placebo response impact, clinical data risk, and stock crashes. Expect deep dive analysis, biotech storytelling, and insights into FDA pathways, trial design flaws, and volatility.
Visit ZLK.com for more info.
Add our WhatsApp Channel.
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
